INTRODUCTION
Transforming growth factor-β (TGF-β) is a member of a large family of growth factors and cytokines which are synthesized by a wide range of cells and therefore are distributed in many different tissues [1] . In humans, three Key words : coronary artery disease, haplotypes, human transforming growth factor-β1, polymorphisms.
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Correspondence : Dr P. Syrris. isoforms have been found (TGF-β1, TGF-β2 and TGF-β3) with great structural and functional similarities [1] . TGF-β1 is the most abundant isoform and is highly conserved in primary sequence through evolution. It is synthesized as precursor latent forms (390 amino acids long) which have no known biological activity [2, 3] . The active form of TGF-β1 is released proteolytically from the precursor form [4] and consists of a disulphide-linked 25-kDa homodimer of two 112 amino acid peptides. The nucleotide and the deduced amino acid sequences of TGF-β1 mRNA were first reported by Derynck et al. [5] , and it was later shown that the coding region of the TGF-β1 gene consists of seven exons and six introns [6] .
A wide variety of functions have been attributed to TGF-β1, e.g. reduction of inflammation and promotion of wound healing [7] , immunosuppression [8, 9] , regulation of cell proliferation, differentiation and migration (reviewed by Massague! [1] ), and regulation of extracellular matrix production [10, 11] . Also, various studies have shown that TGF-β1 plays an important role in a number of diseases : cancer [12, 13] , systemic sclerosis [14] , pulmonary fibrosis [15] , osteoporosis [16] and atherogenesis [17] [18] [19] [20] [21] .
In the ' protective cytokine ' hypothesis, active TGF-β1 has been proposed as the key inhibitor of atherogenesis [17, [22] [23] [24] . According to this complex model, active TGF-β1 is an inhibitor of vascular smooth-muscle cell migration and proliferation and therefore prevents the development of atherosclerosis. Furthermore, it is thought that TGF-β1 maintains endothelium function by suppressing leucocyte adhesion to endothelial cells both in the presence and absence of inflammatory cytokines [25] . Various defects in the TGF-β1 biology resulting in low TGF-β1 activity in combination with high levels of circulating lipid and cholesterol may allow pathological changes to occur in the vessel wall and thus initiate the process of atherogenesis [23] . On the other hand, an alternative role for TGF-β1 has been suggested by various studies implicating this cytokine in some pathological processes like vascular restenosis [21] and thrombogenesis [26] .
The aim of this study was to scan the TGF-β1 locus for polymorphisms, to establish the prevalence of each genotype in individuals with coronary artery disease (CAD) and controls and to identify any haplotypes associated with a predisposition to coronary artherosclerosis. While this work was in progress Cambien et al. [27] reported seven polymorphisms in the TGF-β1 gene in patients with myocardial infarction and control subjects (ECTIM study), showing no association between those polymorphisms and the degree of CAD in patients. They also found that the Pro#& allele was associated with lower systolic pressure in the control groups and that a history of hypertension was significantly less frequent in Pro#& carriers than in homozygotes for the Arg#& allele [27] .
METHODS

Study population
We studied two apparently unrelated Caucasian U.K. populations recruited at the Department of Cardiological Sciences, St George's Hospital in London and at the Clinical Sciences Centre, Northern General Hospital in Sheffield. In both cases, patients attended for diagnostic coronary angiography or percutaneous transluminal coronary angioplasty. Written consent was obtained from every participant in the study which was approved by the ethics committees of the two hospitals.
Coronary angiograms were read by eye by two independent cardiologists at the two centres. All subjects were divided into two groups based on the percentage of stenosis of their arteries : (i) cases with at least one stenotic lesion involving 30 % reduction of diameter in one or more epicardial arteries were diagnosed as suffering from CAD, and (ii) control subjects with completely normal coronary arteries (0 % stenosis). From a clinical point of view the latter consisted of angiographically normal patients with chest pain but no other cardiac problem (Syndrome X patients) and others with valvular heart disease. The final number of subjects recruited in each institution was as follows : (i) London : 157 controls, mean age 55n1p13n1 (S.D.) years ; 293 patients with CAD, mean age 62n1p9n33 (S.D.) years (P 0n05) and (ii) Sheffield : 87 controls, mean age 60n2p 9n06 years ; 362 patients with CAD, mean age 58n9p10n4 years (P 0n05). Risk factors of all subjects are summarized in Table 1 . Hypertension was defined by a clinical history of hypertension according to standard criteria (systolic blood pressure 160 mmHg and\or diastolic blood pressure 95 mmHg) or treatment with antihypertensive drugs.
Genotyping
Blood from all individuals was collected into sterile tubes containing 0n1 % EDTA and stored at k20 mC. Genomic DNA was extracted using a Nucleon II DNA extraction kit (Scotlab, Bioscience). DNA samples from a small number of controls (30 individuals) were screened for mutations in the TGF-β1 locus by single-strand conformational polymorphism (SSCP). Based on the published sequence of the TGF-β1 gene [5, 28] , overlapping fragments were amplified by polymerase chain reaction (PCR) in order to cover the whole coding region and 1140 bp upstream of this region. All PCRs were carried out using Hybaid and Techne thermal cyclers. For every sample, 1 µg of DNA was used for amplification while the final concentrations of the reagents were 0n75 units of Red Hot Taq DNA polymerase (Advanced Biotechnologies Ltd), 10 µl of PCR buffer [75 mmol\l Tris-HCl, pH 9n0, 20 mmol\l (NH % ) # SO % , 0n01 % Tween (w\v) and 1n5 mmol\l MgCl # ] and 0n2 mmol\l dNTPs (total reaction volume 25 µl). SSCP analysis of the PCR products was performed on 10 % non-denaturing acrylamide gels (NBL) overnight at two different temperatures (4 mC and room temperature). Band patterns were visualized by silver staining or ethidium bromide. DNA from subjects exhibiting a different electrophoretic pattern was purified using a Qiagen gel extraction kit and was subsequently sequenced by an ABI PRISM 377 DNA sequencer (PE Applied Biosystems). After identification of a number of polymorphisms (see Results), controls and patients with CAD were genotyped using a PCR method followed by restricton enzyme digestion. Briefly, DNA from all subjects was specifically amplified by PCR using the conditions detailed in Table 2 . Restriction endonucleases (MaeIII, Eco81I, Sau96I and FokI) were used to identify a haplotype for each subject. On one occasion a primer with a mismatch base pair was introduced in order to genotype the samples for one of the polymorphisms using the enzyme PstI (see Results and Table 2 ). In all cases, after amplification 8 µl of PCR product was completely digested with 1n5 units of the appropriate enzyme and subsequently electrophoresed on 2n5% agarose gels. All the samples were genotyped twice by two individuals who were blinded to their phenotype. Samples from controls and patients were mixed during genotyping and were assigned to different groups during data analysis after the experimental part of the study had been concluded.
Statistical analysis
On the basis of preliminary data on the frequency of two polymorphisms in the promoter region of the TGF-β1 gene (see Results), a two-tailed test was used to determine the minimum size of the study population required to detect a statistically significant difference in allelic frequencies between controls and patients with CAD (significance level 0n05, 90 % power). Hardy-Weinberg equilibrium was tested using a χ# test with one degree of freedom. Disease association with genotype or haplotype was calculated using χ# tests ; the G statistic was also calculated where expected values were small ( 5).
Pairwise linkage disequilibrium constants were calculated according to the method of Chakravarti et al. [29] . The degree of pairwise linkage disequilibrium in controls and cases was calculated for each pair of polymorphisms ; correlation coefficients (∆) are reported using the plus (j) or minus (k) symbols expressing positive or negative linkage disequilibrium respectively.
RESULTS
In this study we screened for mutations the entire coding region of the TGF-β1 gene and 1140 bp upstream of this region in 30 control subjects using PCR-SSCP and sequencing techniques. The presence of five polymorphisms was revealed : two substitutions in the promoter region of the gene at positions k800 (G A) and k509 (C T) and three in the gene coding region for the precursor part of the TGF-β1 protein. Of those, two were in exon 1 : codon 10 (CTG CCG) and codon 25 (CGG CCG) resulting in changes in the amino acid sequence (Leu"! Pro and Arg#& Pro respectively). The last one was located in exon 5 (codon 263, ACC ATC) causing the substitution of a Thr with an Ile (Thr#'$ Ile). All case subjects (n l 655) and controls (n l 244) from both centres in London and Sheffield were genotyped for these five polymorphisms with the use of restriction endonucleases. In the case of the polymorphisms in the promoter region of the gene (G-800A and C-509T), the changes in the DNA sequence result in the abolition of naturally occurring restriction sites for MaeIII and Eco81I respectively. For the expressed polymorphisms Arg#& Pro and Thr#'$ Ile, the presence of the mutant leads to the creation of restriction sites for Sau96I and FokI respectively. In order to genotype samples for the Leu"! Pro polymorphism a reverse mismatch base pair primer was used (A T, codon 11) so that a PstI restriction site was introduced in the presence of the Leu"! allele (Table 2) Table 3 . Genotype and allele frequencies were almost identical in the two study populations and no group or subgroup had a genotype distribution that deviated significantly from that expected for a population in Hardy-Weinberg equilibrium. No statistically significant association was found between any of the five polymorphisms and CAD or hypertension (P 0n05). In particular, the codon 25 polymorphism which has been previously linked with systolic pressure [27] was not associated with hypertension either in the control or the patient groups (London and Sheffield groups combined, P l 0n095).
It was shown that the TGF-β1 polymorphisms were in strong positive or negative linkage disequilibrium with each other (Table 4) . A positive sign in front of the correlation coefficient (∆) indicates that there is an excess of alleles containing the most common base at both polymorphic loci (positive linkage disequilibrium). A negative sign in front of the ∆ value implies that the most common base at one position is more likely to be associated with the least common base at the other position considered (negative linkage disequilibrium). All linkage disequilibrium coefficients were statistically significant except that between codon 25\codon 263 (Table 4) . Due to the small number of homozygotes for the less common alleles the linkage disequilibrium coefficient for the k800\codon 263 polymorphisms was statistically significant in the combined groups (Table 4) but not in the London (∆ lk0n022, 95 % confidence limit k0n087 to 0n044) or the Sheffield group (∆ lk0n045, 95 % confidence limit k0n110 to 0n020) separately.
Haplotypes of the TGF-β1 locus were determined based on the genotypes of all individuals participating in the study [30] . This was achieved by first assigning the haplotypes that could be determined unambiguously, i.e. those that occurred in individuals who were either homozygous at all of the polymorphic loci or homozygous at all of the loci considered except one. The individuals who were heterozygous at two or more loci were then assigned haplotypes by fitting to the unequivocal haplotypes. In cases where it was possible to assign two pairs of haplotypes, the pair corresponding to the most common alleles was used : for example an individual with genotype GG CT CT GG CC would be assigned GCTGC and GTCGC rather than GCCGC and GTTGC as the former pair are the most common unambiguously observed haplotypes. This method allowed the deduction of seven main TGF-β1 haplotypes : GCTGC, GTCGC, ACTGC, GCCCC, GTCGT, GT-TGC and GCCGC (bases are listed in the order G-800A, C-509T, codon 10 -2nd position, codon 25 -2nd position and codon 263 -2nd position). The exact number of controls and patients with CAD for every haplotype is given in Table 5 . There was no significant difference in haplotype distribution between controls and cases and consequently none of the haplotypes was significantly associated wth CAD or hypertension (P 0n05).
DISCUSSION
We have identified five frequent polymorphisms in the promoter region and the coding region of the TGF-β1 gene. While this work was being carried out, Cambien et al. [27] reported the existence of these five polymorphisms in controls and patients with myocardial infarction [27] . Their allele frequencies compare well with those in the two Caucasian U.K. populations studied by our group. Their findings also included two more variants : a C A substitution at position k988 and a C insertion at position j72. The C-988A variant was found to be extremely rare in the ECTIM study (only two carriers in 1192 individuals) and therefore was excluded from any statistical analysis. The j72C polymorphism is located at a part of the TGF-β1 gene which does not correspond to any recognized consensus sequence and it seems unlikely that it plays an important role in modulating the expression of this gene. Furthermore, there is an almost complete association (linkage disequilibrium coefficient l 0n99) between the j72C and codon 25 polymorphisms in the ECTIM study [27] . For the above reasons we decided not to genotype any individuals in our study for those two TGF-β1 variants.
Recent evidence indicates that there is a substantial genetic component to the control of total (acid-activatable latent form of TGF-β plus active TGF-β) and active TGF-β concentration in the circulation. In particular, studies of 139 pairs of female monozygous and dizygous twins have shown a correlation between the two polymorphisms identified in the promoter region of the TGF-β1 gene (G-800A, C-509T) and the concentration of TGF-β1 in human plasma [31] . The G-800A substitution is thought to disrupt a consensus half-site for the binding of the nuclear transcription factor CREbinding protein, and it was found that the presence of the A allele is significantly associated (P 0n05) with lower levels of total TGF-β1 in the circulation [31] . On the other hand, the T allele of the C-509T polymorphism has been associated with higher concentrations of both total and active TGF-β1 [31] . These findings indicate that the G-800A and C-509T polymorphisms may be involved in the modulation of expression of the TGF-β1 gene and therefore a predisposition to atherosclerosis could be linked to particular alleles of this gene.
The other three polymorphisms in the coding region of the gene are located at potentially very important positions for the activation process of the TGF-β1 protein. The first event in this process takes place inside the cell and is the removal of a hydrophobic signal sequence to give pro-transforming growth factor-β1. The pro-TGF-β1 is subsequently cleaved between the Cterminal 112 amino acids and the larger N-terminal peptide. After that step the N-terminal peptides (known as latency associated peptides) remain non-covalently associated with the C-terminal peptides thus forming latent forms of the TGF-β1 protein [2] . The codon 10 and codon 25 polymorphisms are part of the signal peptide sequence and result in changes in the protein sequence : Leu\Pro and Arg\Pro respectively. It is difficult to predict accurately what effect such changes are likely to have on the cleaving process of the signal peptide. However, taking into account the type of the amino acids in question, it seems that the Arg#& Pro substitution at codon 25 could have an effect since a non-polar amino acid (proline) replaces a charged polar one (arginine). On the other hand, the replacement of a non-polar molecule with another (leucine\proline) at codon 10 might be less disruptive. Finally, the Thr#'$ Ile polymorphism at exon 5 is close to the region where latency associated peptide is cleaved from the active part of the protein, suggesting that this polymorphism may also play a role in the activation of TGF-β1. Establishing the three-dimen-sional structure of latency associated peptides could provide some answers as to whether these polymorphisms lead to significant conformational changes in the protein that may inhibit or promote TGF-β1 activation.
TGF-β1 has been proposed as a promoter of differentiation and an inhibitor of proliferation of arterial smooth muscle cells thus playing a role in maintaining the structure of the vessel wall in homoeostasis [23] . It is reasonable to assume that the concentration of TGF-β1 in blood is partly genetically controlled and therefore changes in the TGF-β1 gene could be associated with variable effects on the function of the TGF-β1 protein.
The main objective of this study was to identify polymorphisms in the TGF-β1 gene that might be significantly associated with a predisposition to coronary heart disease. However, no association was shown between any of the TGF-β1 polymorphisms or haplotypes and CAD, suggesting that the presence of those polymorphisms alone is not a genetic risk factor for predisposition to CAD. This lack of association in the present study is unlikely to have been due to a problem of power. For example, the frequency of the A allele (G-800A polymorphism) is approximately 0n085 in Caucasians. Using a two-tailed test (0n05 significance level) with 90 % power to detect an increase of 0n1 in prevalence of the A allele, 241 individuals will be required in each study group. Using the same test, 214 individuals in each study group will be required in order to demonstrate an increase from 0n3 to 0n45 in the frequency of the T allele (C-509T polymorphism). Similarly, this study has the power to detect statistically significant changes in the frequencies of all polymorphisms found in the TGF-β1 gene.
Significant linkage disequilibrium occurs between the polymorphisms of the TGF-β1 locus (Table 4) , pointing to an evolutionary relationship between the biallelic polymorphisms. Having established a haplotype for every individual participating in the study (n l 899) we attempted to determine an ancestral haplotype in humans. It is well known that the amino acid sequence of the TGF-β1 protein is highly conserved across species. In particular, a comparison of TGF-β1 protein sequences from mouse [32] , rat [33] , sheep [34] , cow [35] , pig [36] , green monkey [37] and human [5, 6] reveals that the conserved amino acids at the polymorphic sites in the coding region are proline (codon 10), arginine (codon 25) and threonine (codon 263). This is also supported by a set of experiments involving a small number of various apes including chimpanzees, orangutans and gorillas. In particular, DNA sequencing of exons 1 and 5 of the TGF-β1 gene from 11 animals showed that apes also possessed the same set of conserved amino acids (Pro, codon 10 ; Arg, codon 25 and Thr, codon 263). In order to determine an ancestral genotype for the promoter region of the TGF-β1 gene, individuals from different ethnic groups were genotyped for the G-800A and C-509T polymorphisms.
Briefly, it was found that in 80 individuals of AfroCaribbean origin the C allele of C-509T polymorphism occurred at a higher frequency than in Caucasians (C\T frequency : 0n78\0n22). In contrast, the A allele of the G-800A polymorphism was not detected in over 50 AfroCaribbean individuals analysed, indicating that this allele is either completely absent in the Afro-Caribbean population or its frequency is extremely low compared with that in Caucasians. All this data allows us to conclude that there are two possible ancestral TGF-β1 haplotypes in humans : GCCGC or GTCGC. Based on our observations regarding the allele frequency of the C-509T polymorphism in different ethnic groups, we favour GCCGC as the ancestral TGF-β1 haplotype. We propose that the TGF-β1 haplotypes have arisen based on the following model : (a) GCCGC GCTGC ACTGC, (b) GCCGC GTCGC GTCGT, (c) GCCGC GCCCC and (d) GCCGC GTTGC. In this model all haplotypes were observed unambiguously with the exception of two low-frequency haplotypes (GCCGC and GTTGC). Each of the unequivocally observed haplotypes could have arisen by a single base change in a previously existing haplotype, except GTTGC, which must have been the product of a recombination event. Indeed, crossover between the two most common alleles for the C-509T and codon 10 polymorphisms would have produced two possible haplotypes : GTTGC and GCCGC which is identical to the putative ancestral haplotype.
Studies have indicated that hypertension increases the in vivo expression of TGF-β1 in rat aortic tissue [38] . It was also shown that TGF-β1 mRNA levels in rat aorta increased after sustained pressor infusion of angiotensin II and so it has been postulated that TGF-β1 may participate in the progression and maintenance of chronic hypertension [39] . It therefore seems possible that TGF-β1 may be involved in the regulation of blood pressure. In their study Cambien et al. [27] found that in the control groups, but not in patients with myocardial infarction, the Pro#& allele was significantly associated with a lower systolic pressure (P 0n002). However, these findings appear to be inconsistent with the fact that the frequency of the Pro#& allele was higher in patients with myocardial infarction than in controls [27] . Our findings do not support these results since in our study groups there was no association between the codon 25 polymorphism and hypertension in controls or patients with CAD. However, it must be pointed out that a limitation applies to our study regarding the above findings. Even though the definition of hypertension is essentially identical in the two studies, the data on the association of TGF-β1 polymorphisms with blood pressure are not directly comparable. In the ECTIM study, blood pressure measurements were based on the standardized protocol of the MONICA project [27] which appears to be more stringent in comparison with that used in this study.
In conclusion, it appears that CAD is not linked with the polymorphisms in the TGF-β1 gene reported in this study. However, these findings do not necessarily exclude direct or indirect involvement of TGF-β1 in the progression of cardiovascular disease. A recent study reported that somatic mutations in the gene encoding the type II receptor for TGF-β1 may lead to loss of function of this receptor in cells composing atherosclerotic and restenotic lesions in humans [40] . This would mean that this acquired resistance of vascular cells to TGF-β1 is a key factor in the progression of the disease.
Future work is needed to establish the exact effect that the TGF-β1 polymorphisms may have on the activation process of the protein and its function. We are currently investigating whether any of these polymorphisms are associated with changes in the levels of serum TGF-β1. Also, future studies may determine if the TGF-β1 polymorphisms play a role in other pathological processes like cancer, vascular restenosis and fibrosis.
